All In MedTech

Device Trial Radar · NCT05889390

Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer

[A Prospective, Randomized Trial to Assess the Added Value of Concomitant Modulated Electro-hyperthermia in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy - an Investigator Initiated Study]

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

71

Actual

Start

Feb 20, 2023

Primary completion

Oct 31, 2025

Study completion Jul 31, 2027

Sponsor

Lead sponsor
Semmelweis UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 5, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to investigate whether the application of concomitant modulated electro-hyperthermia in a neoadjuvant chemotherapeutic setting is beneficial for patients with HER2-negative, stage II-III breast cancer.

Conditions

  • HER2-negative Breast Cancer

Interventions

  • Oncotherm EHY-2030Device

    Oncotherm EHY-2030 is a non-invasive electromagnetic devices with known anti-tumoral effects. It operates in a precision capacitive coupled impedance matched way, working on a radiofrequency of 13.56 MHz. mEHT exploits various biophysical differences of cancer cells. For example, energy absorption on the membrane rafts is different than those of healthy host cells, and damage-associated molecular patterns (DAMPS) will also occur leading to programmed or immunogenic tumor cell death. mEHT can enhance DNA fragmentation of tumor cells, increase the fraction of cells with low mitochondrial membrane potential, increase the concentration of intracellular Ca2+, increase the Fas, c-Jun N-terminal kinases and MAPK/ERK signaling pathways, increase the expression of pro-apoptotic Bcl-2 family proteins and can up-regulate the expression of genes associated with the molecular function of cell death (EGR1, JUN, and CDKN1A) and silencing others associated with cytoprotective functions.

  • PaclitaxelDrug

    weekly paclitaxel for 12 weeks

  • CarboplatinDrug

    added to weekly paclitaxel if patient has triple-negative breast cancer

  • Cyclophosphamide/DoxorubicinDrug

    according to the AC protocol

  • Breast cancer removal surgeryProcedure

    Either breast-conserving surgery or total mastectomy after the neoadjuvant chemotherapy with or without mEHT (if feasible)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Residual size of the primary tumor, determined by imaging techniques (in percentage)Time frame: change from baseline at 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University

    Budapest, Budapest, Hungary

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.